Literature DB >> 3416306

Cellular distribution of c-myc transcripts during chemical hepatocarcinogenesis in rats.

P Nagy1, R P Evarts, E Marsden, J Roach, S S Thorgeirsson.   

Abstract

The expression of cellular myc (c-myc) was studied during early and late stages of chemical hepatocarcinogenesis in the rat using Northern blot analysis and in situ hybridization. Hepatocarcinogenesis was induced according to the resistant hepatocyte model of Solt and Farber. An uninitiated version of this model was also used to examine the expression of c-myc during proliferation and differentiation of oval cells. The expression of c-myc was increased throughout hepatocarcinogenesis starting with early preneoplastic foci and oval cells. Similar levels of c-myc transcripts were detected in oval cells and basophilic hepatocytes generated by the uninitiated version of the protocol as were found in preneoplastic foci and oval cells during hepatocarcinogenesis. Whereas c-myc expression remained elevated in late neoplastic nodules and carcinomas, it gradually declined in both "remodelling" nodules and uninitiated livers. Our data indicate that c-myc expression is elevated during the undifferentiated stages of hepatocyte development. Furthermore, the data support the hypothesis that a critical early step in chemical hepatocarcinogenesis involves a block in the normal differentiation program of the hepatocytes.

Entities:  

Mesh:

Year:  1988        PMID: 3416306

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

1.  Interspecies comparison of c-myc gene in human and rat glioma cell lines.

Authors:  H Shindo; E Tani; N Kochi; K Kaba; T Matsumoto; K Miyaji; Y Yamamoto; J Furuyama
Journal:  Acta Neuropathol       Date:  1991       Impact factor: 17.088

Review 2.  Evidence for the stem cell origin of hepatocellular carcinoma and cholangiocarcinoma.

Authors:  S Sell; H A Dunsford
Journal:  Am J Pathol       Date:  1989-06       Impact factor: 4.307

3.  Evolution of neoplastic development in the liver of transgenic mice co-expressing c-myc and transforming growth factor-alpha.

Authors:  E Santoni-Rugiu; P Nagy; M R Jensen; V M Factor; S S Thorgeirsson
Journal:  Am J Pathol       Date:  1996-08       Impact factor: 4.307

4.  Characterization of liver epithelial cells transfected with myc and/or ras oncogenes.

Authors:  S C Strom; J B Faust; E Cappelluti; R B Harris; N D Lalwani
Journal:  Dig Dis Sci       Date:  1991-05       Impact factor: 3.199

5.  Comparative analysis of p53 and c-myc expression and cell proliferation in human hepatocellular carcinomas--an enhanced immunohistochemical approach.

Authors:  M Saegusa; Y Takano; H Kishimoto; G Wakabayashi; K Nohga; M Okudaira
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

Review 6.  Experimental models of hepatocellular carcinoma.

Authors:  Philippa Newell; Augusto Villanueva; Scott L Friedman; Kazuhiko Koike; Josep M Llovet
Journal:  J Hepatol       Date:  2008-01-30       Impact factor: 25.083

7.  Inhibition of neoplastic development in the liver by hepatocyte growth factor in a transgenic mouse model.

Authors:  E Santoni-Rugiu; K H Preisegger; A Kiss; T Audolfsson; G Shiota; E V Schmidt; S S Thorgeirsson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

Review 8.  Fumonisin-induced hepatocarcinogenesis: mechanisms related to cancer initiation and promotion.

Authors:  W C Gelderblom; S Abel; C M Smuts; J Marnewick; W F Marasas; E R Lemmer; D Ramljak
Journal:  Environ Health Perspect       Date:  2001-05       Impact factor: 9.031

9.  Overexpression of hepatic prothymosin alpha, a novel marker for human hepatocellular carcinoma.

Authors:  C G Wu; N A Habib; R R Mitry; P H Reitsma; S J van Deventer; R A Chamuleau
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

10.  Hepatotoxin-induced changes in the adult murine liver promote MYC-induced tumorigenesis.

Authors:  Shelly Beer; Kimberly Komatsubara; David I Bellovin; Masashi Kurobe; Karl Sylvester; Dean W Felsher
Journal:  PLoS One       Date:  2008-06-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.